Drugs / Allodepleted T Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00710892 | Dec 2008 → Nov 2011 overdue | acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allodepleted T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00710892 ↗ |
| Modality | Cell therapy | “Adoptive transfer of donor-derived T lymphocytes expressing a safety switch” PMID 24753538 ↗ Apr 2014 |
| Route | Intravenous | “The specially selected and treated T cells will be given by vein, once.” NCT00710892 ↗ |